CLDN18.2: a potential nanotherapeutic target for cholangiocarcinoma
Frontiers in Pharmacology · 26.03.2025 · 16
DOI: 10.3389/fphar.2025.1559558 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 26.03.2025. Verfasst von Yu Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Yichang Central People's Hospital and The First College of Clinical Medical Science, China Three Gorges University, Yichang, …. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cholangiocarcinoma (CCA) is an extremely malignant and aggressive primary liver tumor that has become increasingly prevalent in recent years. Unfortunately, the prognosis for patients diagnosed with CCA remains exceptionally poor. Currently, the primary treatment options include surgery and chemotherapy. However, the effectiveness of postoperative chemotherapy is limited, characterized by a brief duration of remission and high rates of recurrence and metastasis, resulting in minimal survival benefits for patients. Therefore, there is an urgent need to develop new therapeutic strategies that are both safer and more effective. In recent years, as oncology research has progressed, Claudin 18.2 (CLDN18.2)-targeted therapy has emerged, showing promise for improving the survival of patients with CLDN18.2-positive cancers. Studies suggest that combining new agents targeting CLDN18.2 with standard cytotoxic therapies offers significant survival benefits in CLDN18.2-positive solid tumors, which is expected to provide a more effective treatment option for patients with advanced cholangiocarcinoma. While existing immune checkpoints or therapeutic targets have limitations, such as low positivity rates and minimal absolute improvement in patient survival time, drugs that target FGFR, IDH, and Her-2, along with antiangiogenic agents, have shown promise for patients with advanced malignancies affecting the bile ducts. Therefore, exploring these novel therapeutic strategies may yield new insights for precision treatment of cholangiocarcinoma in the future. This review aims to focus on the potential application of CLDN18.2 in treating solid tumors, particularly cholangiocarcinoma, to systematically summarize research progress related to this target and thoroughly examine its value in diagnosing, treating, and assessing the prognosis of cholangiocarcinoma.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Yichang Central People's Hospital and The First College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei, China.
- Clinical Medical College, YouJiang Medical University for Nationalities, Baise, Guangxi, China.
- Department of Oncology, Affiliated Hospital of YouJiang Medical University for Nationalities/Guangxi Clinical Medical Research Center for Hepatobiliary Diseases, Baise, Guangxi, China.
- Tumor Prevention and Treatment Center of Three Gorges University and Cancer Research Institute of Three Gorges University, Yichang, Hubei, China.
- Clinical Medical Research Center for Precision Diagnosis and Treatment of Lung Cancer and Management of Advanced Cancer Pain of Hubei Province, Wuhan, China.
Zitieren
APA
Huang, Y., Ye, Y., Yi, T., Yuan, C., & Li, D. (2025). CLDN18.2: a potential nanotherapeutic target for cholangiocarcinoma. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1559558
Vancouver
Huang Y, Ye Y, Yi T, Yuan C, Li D. CLDN18.2: a potential nanotherapeutic target for cholangiocarcinoma. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1559558
BibTeX
@article{Huang2025,
author = {Huang, Yu and Ye, Yulu and Yi, Tingzhuang and Yuan, Cheng and Li, Daojun},
title = {CLDN18.2: a potential nanotherapeutic target for cholangiocarcinoma},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1559558}
}
EUVIMED